BPC-157 Half-Life Calculator
BPC-157 has one of the shortest half-lives of any compound people track — it is a small, unmodified peptide with none of the structural modifications that give pharmaceutical peptides their duration. This calculator charts what that means: no accumulation, and complete clearance between administrations.
Half-life 15 min · peaks at 6 min
Every 24 hours.
Half-life
Left at next dose
BPC-157 · once daily · levels plateau after ~1.3 hours
Steady-state peak
0.68 mg
Steady-state trough
0 mg
Accumulation
None
At once daily, each dose has essentially cleared before the next one — levels don't accumulate, they repeat the same rise and fall. Clearance after a dose takes about 1.3 hours.
This is a modelled estimate of relative levels from published half-life and time-to-peak figures — not a measured blood concentration. Individual pharmacokinetics vary.
Based on a published BPC-157 half-life of about 15 min. The chart models RELATIVE levels from a unit dose — enter your own figures to see the shape. It is not a dose recommendation.
What a 15 min half-life means in practice
A half-life of 15 min against once daily dosing means each dose has essentially cleared before the next arrives. That shapes the curve in three ways:
1. One half-life
Half the dose is gone after 15 min. After two half-lives 25% remains, after three 12.5%.
2. What's left at the next dose
Dosing once daily means the next dose lands 24 hours later, with about 0% of the previous one still present.
3. Accumulation and plateau
Almost nothing carries over, so levels don't accumulate — each dose repeats the same rise and fall, clearing in about 1.3 hours.
Worked example
BPC-157 has a half-life of 15 min. Dosing once daily, the next dose arrives 24 hours later with about 0% of the previous one still on board. That's little enough that levels don't build up: each dose rises and falls on its own, clearing in about 1.3 hours.
Why nothing accumulates
Pharmaceutical peptides last for days because they were deliberately engineered to — fatty acids that bind albumin, substituted amino acids that enzymes cannot cut, fusion to a larger carrier. BPC-157 has none of that. It is a short unmodified chain, and peptidases in blood and tissue dismantle it at the rate they dismantle any such molecule.
The practical consequence is that the accumulation question does not arise. At any realistic interval, each administration has cleared long before the next, so there is no plateau, no steady state to reach, and no running total. Every administration reproduces the same rise and fall.
Whether short duration matters depends on whether the proposed mechanism needs sustained presence — which, for a compound with no human efficacy data, is unsettled. The background on BPC-157 covers what the research base actually consists of.
Frequently asked questions
This calculator is provided for informational and educational purposes only and is not medical advice. Always confirm dosing with a qualified healthcare professional and double-check your own measurements before administering anything.
Built by the Pep AI team.